At-Home STI Testing Market

Size, Share & Trends Analysis Report By Infection (HIV, CT), By Test Type (Molecular/NAAT-based Kits, Multiplex Panel Testing), By Sample Type, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033

At-Home STI Testing Market Summary

The global at-home STI testing market size was estimated at USD 2.98 billion in 2025 and is projected to reach USD 5.86 billion by 2033, growing at a CAGR of 8.85% from 2026 to 2033. The rising prevalence of sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, and HIV, along with increasing awareness and demand for private, convenient testing solutions, is significantly driving market growth.

According to the World Health Organization, more than 1 million STIs are acquired every day worldwide, while the Centers for Disease Control and Prevention reports over 2.4 million cases of chlamydia, gonorrhea, and syphilis annually in the U.S. If left undiagnosed and untreated, STIs can lead to severe reproductive health complications, infertility, adverse pregnancy outcomes, and increased HIV transmission risk, underscoring the critical need for accessible screening solutions such as at-home STI testing.

The increasing number of regulatory clearances for fully at-home and over-the-counter STI diagnostic solutions is significantly accelerating market adoption. In March 2025, the U.S. Food and Drug Administration granted marketing authorization to Visby Medical’s Women’s Sexual Health Test, the first fully at-home diagnostic capable of detecting chlamydia, gonorrhea, and trichomoniasis with results in approximately 30 minutes. This milestone marks a major shift toward consumer-operated STI diagnostics, enabling rapid detection without laboratory visits and expanding access to accurate home-based testing.

Advancements in rapid self-testing technologies are further improving accessibility and speed of diagnosis. In October 2025, the FDA approved the INSTI HIV Self-Test from bioLytical Laboratories, a finger-stick blood test delivering results in about one minute, significantly reducing testing barriers and enabling immediate status awareness. In addition, continued availability of oral-fluid rapid tests such as OraQuick supports broader HIV screening uptake through painless, user-friendly self-testing options. These innovations enhance convenience and privacy, further driving consumer adoption.

Technological innovation in molecular and multiplex STI testing is expanding the clinical reliability and scope of home diagnostics. New home-collected molecular tests enable simultaneous detection of multiple infections from a single specimen, improving screening efficiency and patient compliance. For example, multiplex STI testing solutions capable of detecting infections such as chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium from one sample are being deployed through telehealth-enabled care pathways, improving comprehensive sexual health screening and follow-up care. The expansion of multiplex testing is increasing diagnostic accuracy while enhancing the value proposition of at-home screening.

Public health initiatives and digital health distribution programs are also expanding access to home STI testing among high-risk and underserved populations. Programs such as the CDC-supported Together TakeMeHome initiative have distributed hundreds of thousands of free at-home HIV self-tests across the U.S., improving early detection and reaching first-time testers. In parallel, governments and healthcare systems increasingly recognize home testing as a critical strategy to improve screening rates, reduce stigma barriers, and support early treatment. These initiatives are strengthening the role of at-home STI testing in preventive healthcare and disease control strategies.

However, factors such as concerns regarding diagnostic accuracy, improper sample collection, and user interpretation errors can affect test reliability, particularly for self-administered rapid tests, which are anticipated to restrain market growth. Reimbursement limitations and out-of-pocket costs may restrict adoption in price-sensitive markets, especially where public health programs primarily support clinic-based screening. Privacy concerns related to digital result reporting and telehealth integration also continue to influence consumer trust. Furthermore, variability in regulatory frameworks and quality standards across countries creates barriers for manufacturers seeking global expansion.

Global At-home STI Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global at-home STI testing market report based on infection, test type, sample type, distribution channel, and region:

• Infection Outlook (Revenue, USD Million, 2021 - 2033)
• HIV
• Chlamydia (CT)
• Gonorrhea (NG)
• Syphilis
• Trichomoniasis
• HPV
• Hepatitis B & C
• Others
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Rapid Lateral Flow Immunoassays
• Molecular / NAAT-based Kits
• Multiplex Panel Testing
• Others
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Blood
• Urine
• Oral Fluid/Saliva
• Vaginal Swab
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Online Pharmacies & D2C Platforms
• Retail Pharmacies
• Public Health Distribution Programs
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• UK
• Germany
• France
• Italy
• Spain
• Norway
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more